Action 2696 SHANGHAI HENLIUS BIOTECH, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Shanghai Henlius Biotech, Inc.

Actions

2696

CNE100003N76

Temps Différé Hong Kong S.E.
Autres places de cotation
 07:26:00 29/04/2024 		Varia. 5j. Varia. 1 janv.
16,6 HKD +0,61 % Graphique intraday de Shanghai Henlius Biotech, Inc. +8,78 % +19,42 %
26/04 Le médicament anticancéreux de Shanghai Henlius Biotech reçoit le feu vert de la FDA américaine MT
24/04 Shanghai Henlius Biotech administre le premier patient d'une étude clinique sur un médicament contre la fibrose en Chine MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China
Shanghai Henlius Biotech, Inc. - IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI Approved by NMPA
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints
Shanghai Henlius Biotech Turns to Profit in 2023
Shanghai Henlius Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Henlius Biotech Doses First Patient in Phase 1 Clinical Trial of Cancer Drug
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection
Shanghai Henlius Biotech's Fibrosis Drug Gets Chinese Authorities' Nod for Clinical Trials
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration
Shanghai Henlius Biotech Expects Record Full-Year Profit
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 2696
  4. Actualités Shanghai Henlius Biotech, Inc.
  5. Autres langues